DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/qvg8g2/female_hypoactive) has announced the addition of the "Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2014" report to their offering.
This report provides comprehensive information on the therapeutic development for Female Hypoactive Sexual Desire Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Female Hypoactive Sexual Desire Disorder and special features on late-stage and discontinued projects.
The report enhances decision-making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MoAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Apricus Biosciences, Inc.
- Palatin Technologies, Inc.
- ANI Pharmaceuticals, Inc.
- Fabre-Kramer Pharmaceuticals, Inc.
Drug Profiles
- flibanserin
- testosterone
- alprostadil
- TGFK-09SD-ER
- bremelanotide
- (sildenafil + testosterone)
- (bupropion + trazodone hydrochloride)
- (buspirone hydrochloride + testosterone)
For more information visit http://www.researchandmarkets.com/research/qvg8g2/female_hypoactive.
